<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001915'>Aplastic anemia</z:hpo>, <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_512'>myeloproliferative diseases</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>) are stem cell disorders </plain></SENT>
<SENT sid="1" pm="."><plain>There is no clear-cut demarcation of them </plain></SENT>
<SENT sid="2" pm="."><plain>Hypoplastic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> displays features of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, on the other side mixed myelodysplastic and myeloproliferative syndromes (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-MPS) develop </plain></SENT>
<SENT sid="3" pm="."><plain>In our collection of 566 MDS patients, features of <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> as well as myeloproliferation, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-MPS, were present in 25 patients (4.4%) </plain></SENT>
<SENT sid="4" pm="."><plain>Twelve patients had at the time of diagnosis megakaryocytic proliferation and <z:e sem="disease" ids="C0836924" disease_type="Disease or Syndrome" abbrv="">thrombocythemia</z:e> beside signs of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, and seven had <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> with granulocytic proliferation and <z:hpo ids='HP_0001974'>leukocytosis</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>In another six patients, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> was the first diagnosis and the proliferative phase developed later during the course of the disease </plain></SENT>
<SENT sid="6" pm="."><plain>These patients can be characterized as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-MPS in evolution </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> subjects had a variable degree of <z:hpo ids='HP_0001903'>anemia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>While the level of <z:e sem="disease" ids="C0836924" disease_type="Disease or Syndrome" abbrv="">thrombocythemia</z:e> has been relatively stable, the number of leukocytes has been progressive, but rarely extended beyond 100 x 10(9)/l </plain></SENT>
<SENT sid="9" pm="."><plain>Ring-sideroblasts and <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> were frequent findings </plain></SENT>
<SENT sid="10" pm="."><plain>Two more homogeneous <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-MPS groups emerged in our analysis: <z:hpo ids='HP_0001924'>sideroblastic anemia</z:hpo> with <z:e sem="disease" ids="C0836924" disease_type="Disease or Syndrome" abbrv="">thrombocythemia</z:e> and a group fulfilling the criteria of Philadelphia chromosome negative and bcr-abl negative "atypical <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (aCML)' </plain></SENT>
<SENT sid="11" pm="."><plain>One patient with <z:e sem="disease" ids="C0836924" disease_type="Disease or Syndrome" abbrv="">thrombocythemia</z:e> and three with <z:hpo ids='HP_0001974'>leukocytosis</z:hpo> (23%) transformed to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="12" pm="."><plain>Men prevailed (12/13) in patients with <z:hpo ids='HP_0001974'>leukocytosis</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-MPS in evolution </plain></SENT>
<SENT sid="13" pm="."><plain>Of the 46% <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-MPS patients with chromosomal aberrations, del(20)(q) is of interest </plain></SENT>
</text></document>